大剂量甲氨蝶呤治疗血液肿瘤的临床现状分析  

Analysis of clinical status of high-dose methotrexate in the treatment of hematological tumors

作　　者：杜瑞婵 谢灵灵 DU Rui-chan;XIE Ling-ling(The First Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China)

机构地区：[1]重庆医科大学附属第一医院,重庆400000

出　　处：《医学食疗与健康》2021年第7期5-5,15,共2页Medical Diet and Health

摘　　要：目的:评估血液肿瘤患者大剂量甲氨蝶呤(HDMTX)治疗现状。方法:收集81例接受HDMTX治疗的血液肿瘤患者的病例资料,评估其HDTMX治疗规范性。结果:患者化疗期间均接受碱化、水化处理,碱化覆盖率为93.83%;化疗不良反应发生率为43.21%。结论:血液肿瘤患者HDMTX治疗的规范性尚可。碱化覆盖率、不良反应防控工作仍有一定提升空间。Objective:To evaluate the status of high dose methotrexate(HDMTX)therapy in patients with blood tumors.Methods:The data of 81 patients with blood tumor receiving HDMTX treatment were collected to evaluate their HDTMX treatment standard.Results:All patients were treated with alkalization and hydration during chemotherapy,the coverage rate was 93.83%,and the incidence of adverse reactions was 43.21%.Conclusions:The standard of HDMTX treatment for patients with blood tumor is good.Alkali coverage,adverse reaction prevention and control work still has some room for improvement.

关 键 词：HDMTX 血液肿瘤 不良反应 

分 类 号：R733[医药卫生—肿瘤]